Search results for "SIM"

showing 10 items of 10139 documents

Investigation of Isoindolo[2,1-a] quinoxaline-6-imines as Topoisomerase I Inhibitors with Molecular Modeling Methods

2017

Background: Isoindolo[2,1-alpha] quinoxalines constitute an important class of compounds which demonstrated potent antiproliferative activity against different human tumor cell lines and topoisomerase I inhibitors. In particular, their water soluble imine or iminium salts recently synthesized showed potent growth inhibitory effect on NCI-60 tumor cell line panel and biological studies performed on the most active compounds demonstrated that they cause DNA damage via topoisomerase I poisoning. Objective: Herein, we investigate with molecular modeling methods, the common features responsible for topoisomerase I inhibition of the water-soluble isoindolo[2,1-alpha] quinoxalin-6-imines, by compa…

0301 basic medicine030103 biophysicsMolecular modelStereochemistryDNA damageAntineoplastic AgentsIsoindolesTopoisomerase-I InhibitorCrystallography X-RayaromatechinStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundQuinoxalinetopotecanantiproliferativeCell Line TumorNeoplasmsQuinoxalinesquinoxalineDrug DiscoveryHumansCell Proliferationbiologypharmacophore modelTopoisomeraseIminiumGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaMolecular Docking SimulationTopoisomerase IindenoisoquinolineDNA Topoisomerases Type IchemistryDocking (molecular)dockingbiology.proteinMolecular MedicineTopoisomerase I; quinoxaline; antiproliferative; topotecan; aromatechin; indenoisoquinoline; docking; pharmacophore modelIminesTopoisomerase I InhibitorsPharmacophore
researchProduct

2,3-Dihydrobenzofuran privileged structures as new bioinspired lead compounds for the design of mPGES-1 inhibitors

2016

International audience; 2,3-Dihydrobenzofurans are proposed as privileged structures and used as chemical platform to design small compound libraries. By combining molecular docking calculations and experimental verification of biochemical interference, we selected some potential inhibitors of microsomal prostaglandin E2 synthase (mPGES)-1. Starting from low affinity natural product 1, by our combined approach we identified the compounds 19 and 20 with biological activity in the low micromolar range. Our data suggest that the 2,3-dihydrobenzofuran derivatives might be suitable bioinspired lead compounds for development of new generation mPGES-1 inhibitors with increased affinity.

0301 basic medicine300323-Dihydrobenzofuran privileged structure; Cancer; Inflammation; Molecular docking; mPGES-1 inhibitors; Biochemistry; Clinical Biochemistry; Molecular Biology; Molecular Medicine; Organic Chemistry; Drug Discovery3003 Pharmaceutical Science; 3003Amino Acid MotifsClinical BiochemistryGene ExpressionPharmaceutical Science01 natural sciencesClinical biochemistryBiochemistry[ CHIM ] Chemical SciencesProtein Structure Secondary[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compoundLow affinityDrug DiscoveryEnzyme Inhibitors23-Dihydrobenzofuran privileged structure; Molecular docking; mPGES-1 inhibitors; Cancer; InflammationProstaglandin-E SynthasesCancerAnti-Inflammatory Agents Non-SteroidalBiological activityProto-Oncogene Proteins c-metIntramolecular OxidoreductasesMolecular Docking SimulationMolecular dockingMolecular Medicinelipids (amino acids peptides and proteins)Cell SurvivalStereochemistryMolecular Sequence Data2Antineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer3-Dihydrobenzofuran privileged structureInhibitory Concentration 50Structure-Activity Relationship03 medical and health sciencesCell Line TumorMicrosomesHumans[CHIM]Chemical SciencesMolecular BiologyBenzofuransInflammationNatural product010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryEpithelial CellsmPGES-1 inhibitorsCombinatorial chemistryCombined approach0104 chemical sciences030104 developmental biologychemistryDrug DesignDrug Screening Assays Antitumor
researchProduct

Epimagnolin A, a tetrahydrofurofuranoid lignan from Magnolia fargesii, reverses ABCB1-mediated drug resistance.

2018

Abstract Background Epimagnolin A is an ingredient of the Chinese crude drug Shin-i, derived from the dried flower buds of Magnolia fargesii and Magnolia flos, which has been traditionally used for the treatment of allergic rhinitis and nasal congestion, empyema, and sinusitis. The pharmacokinetic activity of epimagnolin A remains to be evaluated. Purpose In this study, we examined the possible interactions of epimagnolin A with human ATP-binding cassette (ABC) transporter ABCB1, a membrane protein vital in regulating the pharmacokinetics of drugs and xenobiotics. Study design/methods The interaction of epimagnolin A with ABCB1 was evaluated in calcein, ATPase, and MTT assays by using Flp-I…

0301 basic medicineATP Binding Cassette Transporter Subfamily BATPasePharmaceutical ScienceATP-binding cassette transporterPharmacologyCrude drugLignans03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsCell Line TumorDrug DiscoverymedicineHumansEnzyme kineticsP-glycoproteinPharmacologyAdenosine TriphosphatasesbiologyAntineoplastic Agents PhytogenicDrug Resistance MultipleCalceinMolecular Docking Simulation030104 developmental biologyComplementary and alternative medicinechemistryVerapamilDrug Resistance NeoplasmMagnolia030220 oncology & carcinogenesisbiology.proteinMolecular MedicineVerapamilmedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Cytotoxicity of sesquiterpene alkaloids from Nuphar plants toward sensitive and drug-resistant cell lines.

2018

Multi-drug resistance (MDR) is a critical problem in cancer chemotherapy. MDR causes the overexpression of ATP-binding cassette (ABC) transporters and mutations in tumor suppressor genes and oncogenes. To tackle this issue, in this study, we focused on Nuphar plants, which have been traditionally used as food. Sesquiterpene alkaloids (1–3) were isolated from N. japonicum and dimeric sesquiterpene thioalkaloids (4–10) were isolated from N. pumilum. P-glycoprotein-overexpressing CEM/ADR5000 cells were cross-resistant to 6,6′-dihydroxythiobinupharidine (10). Using in silico molecular docking, we calculated the binding energies and simulated the interactions of these compounds with the correspo…

0301 basic medicineATP Binding Cassette Transporter Subfamily BTumor suppressor geneCell SurvivalATP-binding cassette transporterNuphar03 medical and health sciences0302 clinical medicineAlkaloidsCell Line TumorNeoplasmsATP Binding Cassette Transporter Subfamily G Member 2HumansATP Binding Cassette Transporter Subfamily B Member 1Binding siteCytotoxicityGeneOncogeneChemistryPlant ExtractsABCB5General MedicineMolecular biologyAntineoplastic Agents PhytogenicNeoplasm ProteinsGene Expression Regulation NeoplasticMolecular Docking Simulation030104 developmental biologyCell cultureDrug Resistance Neoplasm030220 oncology & carcinogenesisSesquiterpenesFood ScienceFoodfunction
researchProduct

Consequences of single-locus and tightly linked genomic architectures for evolutionary responses to environmental change

2020

AbstractGenetic and genomic architectures of traits under selection are key factors influencing evolutionary responses. Yet, knowledge of their impacts has been limited by a widespread assumption that most traits are controlled by unlinked polygenic architectures. Recent advances in genome sequencing and eco-evolutionary modelling are unlocking the potential for integrating genomic information into predictions of population responses to environmental change. Using eco-evolutionary simulations, we demonstrate that hypothetical single-locus control of a life history trait produces highly variable and unpredictable harvesting-induced evolution relative to the classically applied multi-locus mo…

0301 basic medicineAcademicSubjects/SCI011400106 biological sciencesLinkage disequilibriumMultifactorial Inheritanceevolutionary simulationEnvironmental changeGenetic LinkageJhered/401 natural sciencesGenetics (clinical)recombination rate0303 health scienceseducation.field_of_studystructural genomic variationInheritance (genetic algorithm)Adaptation PhysiologicalBiological Evolutionclimate changePerspectiveTraitympäristönmuutoksetBiotechnologyPopulationevoluutioEnvironmentBiology010603 evolutionary biologyLife history theory03 medical and health sciencesVDP::Matematikk og Naturvitenskap: 400::Basale biofag: 470GeneticsEvolutionary dynamicseducationMolecular BiologySelection (genetic algorithm)030304 developmental biologygeenitModels GeneticGenetic Driftilmastonmuutoksetgenetic architectureGenetic architectureEditor's Choice030104 developmental biologyEvolutionary biologyperimäGene-Environment InteractionAdaptationlinkage disequilibrium
researchProduct

Effect of ABC transporter expression and mutational status on survival rates of cancer patients

2020

ATP-binding cassette (ABC) transporters mediate multidrug resistance in cancer. In contrast to DNA single nucleotide polymorphisms in normal tissues, the role of mutations in tumors is unknown. Furthermore, the significance of their expression for prediction of chemoresistance and survival prognosis is still under debate. We investigated 18 tumors by RNA-sequencing. The mutation rate varied from 27,507 to 300885. In ABCB1, three hotspots with novel mutations were in transmembrane domains 3, 8, and 9. We also mined the cBioPortal database with 11,814 patients from 23 different tumor entities. We performed Kaplan-Meier survival analyses to investigate the effect of ABC transporter expression …

0301 basic medicineAdultMaleMutation rateNonsense mutationSingle-nucleotide polymorphismATP-binding cassette transporterRM1-950BiologyMultidrug resistanceP-glycoproteinPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNeoplasmsmedicineMissense mutationHumansSurvival analysisAgedCancerPharmacologyAged 80 and overPrognostic factorSequence Analysis RNACancerABCB5General MedicineMiddle AgedSurvival analysismedicine.diseaseMolecular Docking SimulationSurvival Rate030104 developmental biologyABC transporters030220 oncology & carcinogenesisMutationCancer researchATP-Binding Cassette TransportersFemaleTherapeutics. PharmacologyBiomedicine & Pharmacotherapy
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Can…

2017

AbstractSomatic mutations of the Estrogen Receptor α (ERα) occur with an up to 40% incidence in ER sensitive breast cancer (BC) patients undergoing prolonged endocrine treatments. These polymorphisms are implicated in acquired resistance, disease relapse, and increased mortality rates, hence representing a current major clinical challenge. Here, multi-microseconds (12.5 µs) molecular dynamics simulations revealed that recurrent ERα polymorphisms (i. e. L536Q, Y537S, Y537N, D538G) (mERα) are constitutively active in their apo form and that they prompt the selection of an agonist (active)-like conformation even upon antagonists binding. Interestingly, our simulations rationalize, for the firs…

0301 basic medicineAgonistModels MolecularBreast cancerComputational chemistryMolecular dynamicsSomatic cellmedicine.drug_classlcsh:MedicineEstrogen receptorBreast Neoplasms-Molecular Dynamics SimulationPolymorphism Single NucleotideArticleProtein Structure SecondaryEstrogen Receptor Antagonists03 medical and health sciences0302 clinical medicineBreast cancermedicineEndocrine systemHumanslcsh:ScienceMultidisciplinarybusiness.industrylcsh:REstrogen Receptor alphamedicine.diseaseEstrogen Receptor Antagonist030104 developmental biologySelective estrogen receptor modulator030220 oncology & carcinogenesisCancer researchlcsh:QFemaleEstrogen Receptor AntagonistsbusinessEstrogen receptor alphaBreast NeoplasmHuman
researchProduct

AMG900 as novel inhibitor of the translationally controlled tumor protein

2020

Abstract Introduction Cancer is one of the leading causes of death worldwide. Classical cytotoxic chemotherapy exerts high side effects and low tumor selectivity. Translationally controlled tumor protein (TCTP) is a target for differentiation therapy, a promising, new therapeutic approach, which is expected to be more selective and less toxic than cytotoxic chemotherapy. The aim of the present investigation was to identify novel TCTP inhibitors. Methods We performed in silico screening and molecular docking using a chemical library of more than 31,000 compounds to identify a novel inhibitor of TCTP. We tested AMG900 in vitro for binding to TCTP by microscale thermophoresis and co-immunoprec…

0301 basic medicineApoptosisCell Cycle ProteinsToxicologyResting Phase Cell CycleFlow cytometry03 medical and health sciences0302 clinical medicineCyclin D1Differentiation therapyCell Line TumorNeoplasmsTranslationally-controlled tumor proteinBiomarkers TumormedicineHumansCyclin D3medicine.diagnostic_testbiologyChemistryG1 PhaseTumor Protein Translationally-Controlled 1General MedicineMolecular Docking SimulationBlot030104 developmental biologyProtein Biosynthesis030220 oncology & carcinogenesisCancer cellMCF-7 CellsCancer researchbiology.proteinPhthalazinesCyclin-dependent kinase 6Chemico-Biological Interactions
researchProduct

Assembly rules of helminth parasite communities in grey mullets: combining components of diversity.

2020

Abstract Organisms aggregate in ecological communities. It has been widely debated whether these associations are explained by deterministic or, in contrast, random processes. The answer may vary, depending on the level of an organisational scale (α, β and γ) and the facet of diversity considered: taxonomic, functional and phylogenetic. Diversity at the level of a sampling unit (i.e. host individual) is the α diversity; β diversity represents the extent of dissimilarity in diversity among sampling units (within a level of an organisational scale, β1; between levels of an organisational scale, β2); and the total diversity of a system is γ diversity. Thus, the combination of facets and levels…

0301 basic medicineAssembly rules030231 tropical medicineBiology03 medical and health sciencesFunctional diversity0302 clinical medicineLimiting similarityHelminthsMediterranean SeaHelminthsParasite hostingAnimals[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology14. Life underwaterPhylogenyPhylogenetic treeEcologyrespiratory systemSmegmamorphaPhylogenetic diversity030104 developmental biologyInfectious DiseasesTraitParasitology[SDE.BE]Environmental Sciences/Biodiversity and Ecologyhuman activitiesInternational journal for parasitology
researchProduct